Harad/Haritaki

Terminalia chebula
Harad/Haritaki (Terminalia chebula) is a revered Ayurvedic fruit, a key component of Triphala, widely prevalent across South Asia. Traditionally, it's claimed to balance Vata, Pitta, and Kapha doshas, and is often used for its supposed digestive and laxative properties. Its diverse applications have made it a cornerstone in traditional remedies.
PLANT FAMILY
Combretaceae (White Mangrove)
PARTS USED
Fruit, Seed
AYURVEDIC ACTION
Vata ↓, Pitta ↓, Kapha =
ACTIVE COMPOUNDS
Chebulagic acid (10-20%)

What is Harad/Haritaki?

Haritaki, commonly known as Harad, is the fruit of the *Terminalia chebula* tree, a deciduous tree native to South Asia. It is a small, ribbed, ovoid fruit that ripens to a yellowish-brown color. Revered in traditional Ayurvedic medicine, Haritaki is a key component of Triphala, a well-known herbal formulation.

Its diverse applications stem from its complex chemical composition, which includes tannins, chebulagic acid, and other bioactive compounds, contributing to its astringent and laxative properties.

Other Names of Haritaki

  • Chebulic Myrobalan
  • Black Myrobalan
  • Ink Nut
  • Kadukkai (Tamil)
  • Harda (Hindi)

Benefits of Harad/Haritaki

Heading

<h3> Absolute Contraindications of Harad/Haritaki </h3> <h4>Men actively trying to conceive</h4> <ul> <li>🧬</li> <li>Recommendation: Avoid regular oral Haritaki if you and your partner are trying to father a child; stop and discuss options with a doctor if you’ve been using it regularly.</li> <li>Reasoning: Animal studies show that Terminalia chebula extracts can markedly reduce sperm count, motility and fertility indices; effects were reversible after stopping but fertility was significantly suppressed during use.</li> <li>Scientific_Study_Title: Inhibition of hyaluronidase activity of human and rat spermatozoa in vitro and antispermatogenic activity in rats in vivo by Terminalia chebula, a flavonoid rich plant.</li> <li>Scientific_Study_Authors: S. K. Somasundaram, A. R. M. Raghuveer, et al. (as indexed)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/19903524/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: The study demonstrated strong in-vitro inhibition of sperm hyaluronidase and, with repeated oral dosing in male rats, produced significant decreases in sperm count and motility plus abnormal sperm morphology leading to near-complete contraceptive efficacy at higher doses. The authors reported marked reduction in fertility outcomes in treated males compared with controls, indicating a clear antispermatogenic effect attributable to flavonoid/tannin constituents.</p> <p>The effect was dose-dependent and reversible after treatment cessation, but while taking high or repeated doses the animals were essentially infertile-supporting a clear contraindication for men seeking conception.</p> </li> </ul> <h4>Pre-existing severe liver or renal impairment</h4> <ul> <li>⚠️</li> <li>Recommendation: Avoid self-administration of Haritaki at therapeutic or high doses if you have active severe liver or kidney disease; consult your physician before any use.</li> <li>Reasoning: Repeated high-dose exposures in animal studies produced changes in serum markers (AST, urea) and modest disturbances in liver and kidney function; this indicates that high or prolonged doses can stress these organs.</li> <li>Scientific_Study_Title: Repeated oral dose toxicity study on hydrolysable tannin rich fraction isolated from fruit pericarps of Terminalia chebula Retz in Wistar albino rats.</li> <li>Scientific_Study_Authors: (as indexed in PubMed) R. S. et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/29233773/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: In a 28-day repeated-dose study the hydrolysable tannin-rich fraction of Terminalia chebula at high doses (1000 mg/kg) produced reduced food/water intake and body weight, and statistically significant increases in serum urea, glucose and AST compared with controls, indicating mild disturbances in renal and hepatic function under those experimental conditions.</p> <p>The authors conclude that prolonged exposure to high concentrations of the tannin fraction can affect liver and kidney parameters-supporting caution or avoidance in individuals with compromised hepatic or renal reserve.</p> </li> </ul> <h4>High-dose or prolonged unsupervised use (chronic self-medication)</h4> <ul> <li>⏳</li> <li>Recommendation: Do not self-administer large doses of Haritaki daily for long periods without medical supervision; periodic monitoring of liver and kidney tests is advisable for long-term users.</li> <li>Reasoning: Toxicology studies indicate that while single acute doses may be tolerated, repeated high exposures can change metabolic markers and cause weight/appetite changes; safe chronic dosing has not been firmly established in humans.</li> <li>Scientific_Study_Title: Mutagenicity and oral toxicity studies of Terminalia chebula.</li> <li>Scientific_Study_Authors: (as indexed) Hsu et al. / relevant authors in PubMed record.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/21538627/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: The mutagenicity assays and short-term oral toxicity evaluations indicated no mutagenic signal up to test limits and no mortality after single high doses, but other repeated-dose investigations (see other toxicology reports) point to physiologic changes with sustained high dosing. Therefore, chronic high-dose use warrants caution because long-term safety data in humans are limited.</p> </li> </ul> <h3> Relative Contraindications of Harad/Haritaki </h3> <h4>Concurrent use with antidiabetic medications (insulin, sulfonylureas, etc.)</h4> <ul> <li>🩺</li> <li>Recommendation: If you are on glucose-lowering drugs, consult your provider and monitor blood glucose closely if Haritaki is used; dose reductions of hypoglycemic drugs may be necessary.</li> <li>Reasoning: Multiple animal and in vitro studies show Haritaki extracts reduce blood glucose by inhibiting digestive carbohydrate enzymes and enhancing insulin action - this can potentiate the effect of prescribed antidiabetic drugs and increase hypoglycemia risk.</li> <li>Scientific_Study_Title: Long-term effects of Terminalia chebula Retz. on hyperglycemia and associated hyperlipidemia... (streptozotocin-induced diabetic rats)</li> <li>Scientific_Study_Authors: (as indexed) relevant authors of the PubMed record.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/18058598/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: In streptozotocin-diabetic rat models, aqueous extract of T. chebula at 200 mg/kg produced significant reductions in blood glucose, glycated hemoglobin and improved lipid profiles over chronic administration, indicating robust antihyperglycemic activity that could add to pharmaceutical glucose lowering when combined.</p> </li> </ul> <h4>Concomitant use with drugs metabolized by CYP2C19 and CYP2E1</h4> <ul> <li>🧪</li> <li>Recommendation: Use caution and consult a clinician or pharmacist if you take drugs primarily cleared by CYP2C19 or CYP2E1 (e.g., some proton pump inhibitors, clobazam/clonazepam substrates, isoniazid/acetaminophen pathways); monitoring or dose adjustment may be needed.</li> <li>Reasoning: Preclinical studies indicate T. chebula extracts can inhibit CYP2C19 and CYP2E1 activity in animal models, potentially altering blood levels of co-administered drugs cleared by these enzymes.</li> <li>Scientific_Study_Title: Effects of Mongolian medicine Terminalia chebula Retz. on 6 CYP450 enzymes in rats.</li> <li>Scientific_Study_Authors: (as indexed) authors of the PubMed/PMC article.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/33425113/ (full text at https://pmc.ncbi.nlm.nih.gov/articles/PMC7791385/)</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: After repeated dosing in rats, T. chebula preparations altered pharmacokinetics of probe drugs and inhibited activities of CYP2C19 and CYP2E1 (other CYP isoforms were less affected). The authors advise caution when combining T. chebula with medications primarily metabolized by those enzymes because co-administration changed drug clearance and exposure in these models.</p> </li> </ul> <h4>Active diarrheal disease, abdominal cramping, or intestinal obstruction</h4> <ul> <li>🚽</li> <li>Recommendation: Avoid Haritaki during active diarrhoea or suspected intestinal obstruction; if you have gastrointestinal pain of unclear cause, see a clinician before using.</li> <li>Reasoning: Haritaki increases gut motility and fecal water content in experimental models; in people with loose stools or obstruction, stimulating intestinal movement may exacerbate symptoms or be unsafe.</li> <li>Scientific_Study_Title: Spasmogenic Activity of the Seed of Terminalia chebula Retz in Rat Small Intestine: In Vivo and In Vitro Studies.</li> <li>Scientific_Study_Authors: (as indexed) authors of the PubMed record.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/22135597/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: The aqueous seed extract increased ileal motility and contractile tension dose-dependently and increased faecal number and water content in vivo; effects were mediated by calcium-channel associated pathways. These pro-motility actions underlie traditional laxative use but support avoiding Haritaki during active diarrhoea or conditions where increased intestinal activity is unsafe.</p> </li> </ul>

Heading

<h4>Loose stools / abdominal cramps</h4> <ul> <li>💩</li> <li>Side effect summary: Haritaki commonly stimulates bowel movements; some users may experience loose stools, increased frequency, or abdominal cramping, especially if taken in higher doses.</li> <li>Recommendation: Reduce dose or stop if loose stools or cramping occur; seek medical care if severe or persistent (dehydration, blood in stool, high fever).</li> <li>Reasoning: Experimental data show Haritaki extracts increase intestinal contractility and fecal water content - the same mechanisms that relieve constipation can produce transient diarrhoea in susceptible people.</li> <li>Severity Level: Mild</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Spasmogenic Activity of the Seed of Terminalia chebula Retz in Rat Small Intestine: In Vivo and In Vitro Studies.</li> <li>Scientific_Study_Authors: (as indexed on PubMed)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/22135597/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: Aqueous extract increased ileal contraction frequency and tension in vitro and raised faecal number and faecal water content in vivo in rats; effects were dose-dependent and reduced by calcium-channel blockade, indicating a pharmacologic pro-motility mechanism that can cause increased bowel motions.</p> </li> </ul> <h4>Elevated liver enzymes / renal parameter changes with high or repeated doses</h4> <ul> <li>🧪</li> <li>Side effect summary: High-dose or prolonged intake of concentrated tannin fractions has been associated with elevated liver enzymes and changes in kidney markers in animal studies.</li> <li>Recommendation: If you plan long-term use, discuss monitoring liver and kidney function with your healthcare provider; stop Haritaki and seek medical advice if you develop jaundice, dark urine, persistent nausea or other signs of liver trouble.</li> <li>Reasoning: Repeated-dose toxicology experiments found increases in AST and serum urea and other metabolic changes at high experimental doses, implying organ stress at such exposures.</li> <li>Severity Level: Moderate</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Repeated oral dose toxicity study on hydrolysable tannin rich fraction isolated from fruit pericarps of Terminalia chebula Retz in Wistar albino rats.</li> <li>Scientific_Study_Authors: (as indexed)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/29233773/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: In a 28-day repeated oral dosing study, animals receiving high doses of the hydrolysable tannin fraction exhibited significant increases in serum urea, glucose and AST compared to controls, along with reduced food/water intake-indicating possible mild hepatic and renal perturbation at high/excessive dosing.</p> </li> </ul> <h4>Low blood sugar when combined with diabetes medicines (risk of hypoglycemia)</h4> <ul> <li>📉</li> <li>Side effect summary: When used alongside antidiabetic medications, Haritaki's glucose-lowering actions can add to pharmaceutical effects and increase the risk of hypoglycemia.</li> <li>Recommendation: Diabetic patients should consult their provider before starting Haritaki; monitor blood glucose closely and adjust medication doses if needed under medical supervision.</li> <li>Reasoning: Multiple in-vivo and in-vitro studies report α-glucosidase inhibition and insulin-sensitizing effects, showing genuine glucose-lowering potential that can interact with drug therapy.</li> <li>Severity Level: Moderate</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Long-term effects of Terminalia chebula Retz. on hyperglycemia and associated hyperlipidemia... (streptozotocin model)</li> <li>Scientific_Study_Authors: (as indexed)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/18058598/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: Chronic oral administration of aqueous T. chebula extract produced substantial reductions in elevated blood glucose and glycosylated hemoglobin in diabetic rats and improved lipid parameters, indicating sustained antihyperglycemic activity that could potentiate prescribed glucose-lowering therapies.</p> </li> </ul> <h4>Reversible effects on male fertility (reduced sperm count and motility)</h4> <ul> <li>🧪</li> <li>Side effect summary: Animal experiments show a clear reduction in sperm quality and fertility during treatment; effects were reversible after treatment stopped in the reported studies.</li> <li>Recommendation: Men planning pregnancy should avoid Haritaki until more human data are available and/or they stop the herb and confirm normal semen parameters through their clinician.</li> <li>Reasoning: Terminalia chebula extracts inhibited sperm enzymes (e.g., hyaluronidase) and caused marked declines in sperm count, motility and normal morphology in treated animals-producing marked fertility reduction while on treatment.</li> <li>Severity Level: Moderate</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Inhibition of hyaluronidase activity of human and rat spermatozoa in vitro and antispermatogenic activity in rats in vivo by Terminalia chebula, a flavonoid rich plant.</li> <li>Scientific_Study_Authors: (as indexed)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/19903524/</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: The authors described potent in-vitro inhibition of sperm hyaluronidase and, with oral dosing in male rodents, significant declines in sperm counts and motility with high contraceptive efficacy; fertility recovered after stopping treatment, indicating reversible antifertility effects in these models.</p> </li> </ul>

Heading

<h4>Antidiabetic drugs (insulin, sulfonylureas, metformin, DPP-4 inhibitors)</h4> <ul> <li>Interaction_Details: Haritaki components lower blood glucose via intestinal enzyme inhibition and improved insulin signaling; when combined with antidiabetic drugs this can produce additive glucose-lowering and risk of hypoglycemia.</li> <li>Severity: Moderate</li> <li>Recommendation: Consult your prescribing clinician; monitor blood glucose closely and consider medication dose adjustment if using Haritaki concurrently.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/18058598/</li> <li>Scientific_Study_Title: Long-term effects of Terminalia chebula Retz. on hyperglycemia and associated hyperlipidemia, tissue glycogen content and in vitro release of insulin in streptozotocin induced diabetic rats.</li> <li>Scientfic_Study_Authors: (authors as indexed in PubMed)</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: In diabetic rat models, chronic administration of T. chebula reduced fasting blood glucose, lowered HbA1c and improved lipid profiles; the extract also influenced hepatic glycogen and serum insulin dynamics, demonstrating a clear pharmacologic glucose-lowering capacity that could interact with diabetes medications clinically.</p> </li> </ul> <h4>Drugs metabolized by CYP2C19 (e.g., some proton pump inhibitors, clopidogrel activation pathways)</h4> <ul> <li>Interaction_Details: Preclinical data indicate Haritaki extracts can inhibit CYP2C19 activity; that may raise or lower active drug concentrations depending on whether the drug requires CYP2C19 for activation or clearance (e.g., clopidogrel activation vs. other drugs clearance).</li> <li>Severity: Moderate</li> <li>Recommendation: If you take drugs mainly cleared or activated by CYP2C19, consult your physician or pharmacist before starting Haritaki; therapeutic drug monitoring or alternative therapy may be advised.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7791385/</li> <li>Scientific_Study_Title: Effects of Mongolian medicine Terminalia chebula Retz. on 6 CYP450 enzymes in rats.</li> <li>Scientfic_Study_Authors: (authors as indexed in the PMC article)</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: After repeated dosing, the T. chebula preparation inhibited activities of CYP2C19 and CYP2E1 probe substrates in rats and altered pharmacokinetic parameters of several probe drugs, supporting potential herb-drug interactions with medications metabolized by these isoenzymes.</p> </li> </ul> <h4>Drugs metabolized by CYP2E1 (e.g., certain sedatives, some analgesic metabolic pathways)</h4> <ul> <li>Interaction_Details: T. chebula inhibition of CYP2E1 could reduce metabolic clearance of CYP2E1 substrates and alter their effects/toxicity profiles (direction depends on drug).</li> <li>Severity: Moderate</li> <li>Recommendation: Discuss with your clinician if you use medications primarily cleared by CYP2E1; monitoring or dose adjustments may be necessary.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7791385/</li> <li>Scientific_Study_Title: Effects of Mongolian medicine Terminalia chebula Retz. on 6 CYP450 enzymes in rats.</li> <li>Scientfic_Study_Authors: (authors as indexed)</li> <li>Scientific_Study_Excerpt: <p>Paraphrase of findings: The rat study showed decreased clearance (increased AUC/Cmax) of CYP2E1 probe drugs after T. chebula exposure, consistent with partial inhibition of CYP2E1 activity; this suggests co-administration may change blood levels of drugs metabolized by this enzyme.</p> </li> </ul> <h4>Anticoagulants / Antiplatelet agents (warfarin, DOACs, aspirin, clopidogrel)</h4> <ul> <li>Interaction_Details: There is theoretical concern because many polyphenol-rich herbs affect platelet function or coagulation, but direct, well-documented clinical interaction data specific to Terminalia chebula are limited or absent.</li> <li>Severity: NA (insufficient direct evidence)</li> <li>Recommendation: Because of theoretical risk and inter-individual response, consult your clinician before combining Haritaki with blood-thinning medications; monitor INR/bleeding signs if co-use occurs.</li> <li>Scientific_Study_Available: NA</li> <li>Scientific_Study_Link: NA</li> <li>Scientific_Study_Title: NA</li> <li>Scientfic_Study_Authors: NA</li> <li>Scientific_Study_Excerpt: <p>No definitive PubMed study demonstrates a direct clinically meaningful interaction between Terminalia chebula and anticoagulants; therefore scientific_Study_Available is marked NA. Theoretical caution is advised due to polyphenol content and known herb-drug interactions seen with other tannin-rich plants.</p> </li> </ul>